Tax Shockwave: Alembic Pharma Faces Rs 332.1 Million Demand Over Input Credit Dispute

Alembic Pharmaceuticals Ltd has received a significant tax demand from the Central Goods and Services Tax (CGST) authorities, totaling Rs 332.1 million. The notice includes Rs 228.3 million in disputed tax and Rs 103.8 million in interest, stemming from alleged irregularities in input tax credit claims. The development has raised concerns over compliance scrutiny in the pharmaceutical sector and its potential financial implications.

 

Key Highlights of the Tax Demand

Regulatory Context and Compliance Landscape

Financial and Operational Impact

SectorWide Implications

As Alembic Pharmaceuticals navigates this tax challenge, the episode underscores the importance of robust compliance frameworks—where precision in tax filings can make the difference between routine audits and costly liabilities.

 

Sources: Economic Times, Business Standard, Moneycontrol, CNBC TV18, Mint Tax Desk, Alembic Corporate Filings, GST Department Circulars